{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:16Z","timestamp":1790720356138,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"JST SPRING","award":["JPMJSP2113"],"award-info":[{"award-number":["JPMJSP2113"]}]},{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","award":["JP22K06863"],"award-info":[{"award-number":["JP22K06863"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","award":["JP21H02646"],"award-info":[{"award-number":["JP21H02646"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mogamulizumab is a humanized anti-CCR4 monoclonal antibody used for relapsed\/refractory adult T-cell leukemia, cutaneous T-cell lymphoma, and\/or S\u00e9zary syndrome. Reports of immune-related adverse events (irAEs) in these patients are increasing, and the association between irAEs and mogamulizumab remains to be elucidated. This study aimed to evaluate the association between mogamulizumab and immune-related adverse events (irAEs), as well as to characterize the irAEs associated with mogamulizumab using data from a large-scale spontaneous reporting system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed an exploratory hypothesis-generating analysis of patients from 1967 to September 2023 using VigiBase, a World Health Organization spontaneous adverse event reporting system database. We performed a disproportionality analysis and determined the reporting odds ratios and information components between the drugs of interest and each irAE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mogamulizumab was associated with some irAEs, including myocarditis, severe cutaneous adverse reactions, hepatitis, and myositis. Mogamulizumab exhibited significantly higher reporting rates of these 4 irAEs compared to the anticancer agents other than mogamulizumab. Conversely, the reporting rate of other irAEs, including endocrine autoimmune diseases induced by immune checkpoint inhibitors, was not significant in patients who received mogamulizumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Mogamulizumab is associated with irAEs, including myocarditis, severe cutaneous adverse reactions, hepatitis, and myositis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf201","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:08:27Z","timestamp":1752138507000},"source":"Crossref","is-referenced-by-count":4,"title":["Pharmacovigilance study for the identification of mogamulizumab-induced immune-related adverse events using a real-world database"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3954-6420","authenticated-orcid":false,"given":"Koji","family":"Miyata","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Izawa-Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Niimura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]},{"name":"Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]},{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizusa","family":"Hyodo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuto","family":"Itokazu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsumi","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuka","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]},{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]},{"name":"Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Okayama University Hospital , Okayama 700-8558,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Okayama University Hospital , Okayama 700-8558,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]},{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1971-7696","authenticated-orcid":false,"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima 770-8503,","place":["Japan"]},{"name":"Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital , Tokushima 770-8503,","place":["Japan"]},{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima 770-8503,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"2025071005081996900_CIT0001","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"2025071005081996900_CIT0002","doi-asserted-by":"publisher","first-page":"e0291772","DOI":"10.1371\/journal.pone.0291772","article-title":"Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors","volume":"18","author":"Fujikawa","year":"2023","journal-title":"PLoS One."},{"key":"2025071005081996900_CIT0003","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/1078-0432.CCR-21-2781","article-title":"Mogamulizumab in combination with nivolumab in a phase I\/II study of patients with locally advanced or metastatic solid tumors","volume":"28","author":"Hong","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2025071005081996900_CIT0004","doi-asserted-by":"publisher","first-page":"7280","DOI":"10.1038\/s41467-021-27574-0","article-title":"Depletion of central memory CD8(+) T cells might impede the antitumor therapeutic effect of Mogamulizumab","volume":"12","author":"Maeda","year":"2021","journal-title":"Nat Commun."},{"key":"2025071005081996900_CIT0005","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1182\/blood.2021013341","article-title":"Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients","volume":"139","author":"de Masson","year":"2022","journal-title":"Blood."},{"key":"2025071005081996900_CIT0006","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-2575","article-title":"Mogamulizumab treatment elicits autoantibodies attacking the skin in patients with adult T-cell leukemia-lymphoma","volume":"25","author":"Suzuki","year":"2019","journal-title":"Clin Cancer Res."},{"key":"2025071005081996900_CIT0007","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1182\/bloodadvances.2020001641","article-title":"Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma","volume":"4","author":"Saito","year":"2020","journal-title":"Blood Adv."},{"key":"2025071005081996900_CIT0008","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jaccas.2021.04.001","article-title":"Mogamulizumab-associated acute myocarditis in a patient with T-cell lymphoma","volume":"3","author":"Kwan","year":"2021","journal-title":"JACC Case Rep."},{"key":"2025071005081996900_CIT0009","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1093\/oncolo\/oyad155","article-title":"Mogamulizumab-associated myositis with and without myasthenia gravis and\/or myocarditis in patients with T-cell lymphoma","volume":"28","author":"Virgen","year":"2023","journal-title":"Oncologist."},{"key":"2025071005081996900_CIT0010","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol."},{"key":"2025071005081996900_CIT0011","doi-asserted-by":"publisher","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev."},{"key":"2025071005081996900_CIT0012","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"2025071005081996900_CIT0013","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint inhibitor-related myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol."},{"key":"2025071005081996900_CIT0014","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/jcph.2187","article-title":"Characterization of immune checkpoint inhibitor-induced myasthenia gravis using the US food and drug administration adverse event reporting system","volume":"63","author":"Niimura","year":"2023","journal-title":"J Clin Pharmacol."},{"key":"2025071005081996900_CIT0015","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41571-021-00597-8","article-title":"Harnessing big data to characterize immune-related adverse events","volume":"19","author":"Jing","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"key":"2025071005081996900_CIT0016","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"2025071005081996900_CIT0017","doi-asserted-by":"publisher","first-page":"e1228","DOI":"10.1634\/theoncologist.2019-0250","article-title":"Serious cutaneous toxicities with immune checkpoint inhibitors in the U.S. food and drug administration adverse event reporting system","volume":"24","author":"Raschi","year":"2019","journal-title":"Oncologist."},{"key":"2025071005081996900_CIT0018","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2025071005081996900_CIT0019","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat Methods Med Res."},{"key":"2025071005081996900_CIT0020","doi-asserted-by":"publisher","first-page":"18817","DOI":"10.1038\/s41598-023-46275-w","article-title":"Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events","volume":"13","author":"Montes-Grajales","year":"2023","journal-title":"Sci Rep."},{"key":"2025071005081996900_CIT0021","doi-asserted-by":"publisher","first-page":"e15634","DOI":"10.1111\/dth.15634","article-title":"Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma","volume":"35","author":"Bagot","year":"2022","journal-title":"Dermatol Ther."},{"key":"2025071005081996900_CIT0022","doi-asserted-by":"publisher","first-page":"e70478","DOI":"10.1002\/cam4.70478","article-title":"Mogamulizumab-associated autoimmune diseases: insights from FAERS database analysis","volume":"13","author":"Zhang","year":"2024","journal-title":"Cancer Med"},{"key":"2025071005081996900_CIT0023","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res."},{"key":"2025071005081996900_CIT0024","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/1346-8138.12419","article-title":"Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis","volume":"41","author":"Yonekura","year":"2014","journal-title":"J Dermatol."},{"key":"2025071005081996900_CIT0025","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1080\/10428194.2021.1888376","article-title":"Clinical characteristics and outcomes of black patients with mycosis fungoides and S\u00e9zary syndrome: a subgroup analysis of the phase III MAVORIC trial","volume":"62","author":"Johnson","year":"2021","journal-title":"Leuk Lymphoma."},{"key":"2025071005081996900_CIT0026","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or s\u00e9zary syndrome","volume":"157","author":"Hirotsu","year":"2021","journal-title":"JAMA Dermatol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf201\/63715907\/oyaf201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf201\/63715907\/oyaf201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:08:28Z","timestamp":1752138508000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf201\/8196038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf201","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyaf201"}}